Eight innovative interventions to improve ART outcomes: Promising or sobering facts?
Precongress Course 15
MEFS Exchange course
Course coordinator(s)
Johnny Awwad (Sidra Medicine - Qatar) and Mohammad Aboulghar (Egyptian IVF-ET Center, Egypt)
Course type
Advanced
Course description
Fertility treatment has come a long way in recent years, with significant technological developments and innovative interventions designed with the promise of improving the success rate and treatment experience for couples struggling with starting a family. Ground-breaking advancements have largely stemmed from extensive research in various experimental models before making their way into clinical practice. In addition to their intended goal of advancing our ability to alter reproductive pathways, these technologies have greatly expanded our understanding of the biology of reproduction. Some, nonetheless, have been hastily introduced into clinical practice with limited evidence to their usefulness, often driven by pressure to try promising innovations before the evidence is available to support their use. Such poorly validated clinical habits brisk of increasing dramatically IVF costs, reducing its affordability and access.
This precongress course discusses some of the innovative technologies which made their way into ART practice in recent years, with the prime focus of evaluating their clinical relevance to improving live births in view of emerging scientific evidence.
Target audience
Fertility specialists, urologists, embryologists, nurses, business partners, and legal professionals.
Educational needs and expected outcomes
Expected educational outcomes and competencies: Interprofessional (Teams and Teamwork); Physician (Medical Knowledge, Practice-based Learning and Improvement).
After participating in this CME precongress activity, participants should be able to:
- Describe the biologic pathways of growth hormone in ovarian folliculogenesis and assess its potential role in improving outcomes in poor responders.
- Understand the working hypotheses for introducing oocyte mitochondrial transfer and evaluate the efficacy and safety of this practice.
- Appraise the clinical evidence for the usefulness of adherence compounds in embryo transfer media and endometrial injury in enhancing endometrial receptivity.
- Define the expanding indications for preimplantation genetic aneuploidy screening and their clinical effectiveness.
- Describe the cost effectiveness of ‘freeze-all for all’ strategies in different clinical situations.
- Describe the pathways of oocyte maturation and appraise the merits of oocyte in vitro maturation in modern ART practice.
- Evaluate the possible role of platelet-rich plasma and mesenchymal stem cells strategies in enhancing endometrial receptivity and ovarian response.
Programme
Sunday 07 July 2024
09:00 - 17:00
PCC15: MEFS Exchange course:Eight innovative interventions to improve ART outcomes: Promising or sobering facts?
Sunday 07 July 2024
09:00 - 17:00: PCC15: MEFS Exchange course:Eight innovative interventions to improve ART outcomes: Promising or sobering facts?:
09:00 - 09:30
Growth hormone for the poor responder: lessons learned from animal models and clinical trials?
09:45 - 10:15
Platelet-rich plasma PRP and Stem cells novelties in ART: Facts or Fads?
10:30 - 11:00
Coffee break
Chair invited, but not yet confirmed
11:00 - 11:30
Embryo glue: a riddle still unresolved?
Daniel Brison, United Kingdom
11:45 - 12:15
Endometrial scratching: to do or not to do?
12:30 - 13:30
Lunch break
13:30 - 14:00
The expanding indications of PGT A: Between hope and hype?
14:15 - 14:45
Freeze-all for all: one size fits all?
Yacoub Khalaf, United Kingdom
15:00 - 15:30
Coffee break
Michel Abou Abdallah, Lebanon
15:30 - 16:00
Oocyte in vitro maturation IVM: Has the time come?
16:15 - 16:45
Oocyte mitochondrial transfer to improve ART outcomes: safety versus efficacy?